Diagnosis and the current trends in multiple myeloma therapy

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 10, 2008, Pages 563-566

  Dmoszyńska, Anna ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Medical University of Lublin Klinika Hematoonkologii i Transplantacji Szpiku AM w Lublinie   (Poland)

Author keywords

Diagnosis; Multiple myeloma; Novel therapies

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; DRUG MEGADOSE; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; REVIEW; TREATMENT OUTCOME;

EID: 55849145136     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.490     Document Type: Review

References (19)

1. Gibson J, Joshua D. Epidemiology of plasma cell disorders. In: Myeloma, ed. Dunitz Ltd., London, 2002: 139-150.
2. Durie BGM, Harousseau JL, San Miguel J, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
3. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23: 3412-3420.
4. Dmoszyńska A. [Current views on myeloma treatment]. Acta Haemat Pol. 2006; 37: 37-47. Polish.
5. Cavo M, Zamagni E, Cellini C, et. al. Single versus tandem autologous transplants in multiple myeloma: Italian experience. J Clin Oncol. 2007; 25: 2434-2441.
6. Goldschmidt H. Single versus double high-dose therapy in multiple myeloma: second analysis of the trial GMMG-HD2 (abstract). Hematol J. 2005; 90: 38.
7. Bruno B, Rotta M, Patriarca F, et. al. A comparison of allografting with autografting for newly diagnosed myeloma. N Eng J Med. 2007; 356: 1110-1120.
8. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007; 82: 323-341.
9. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006; 107: 3474-3480.
10. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006; 367: 825-831.
11. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24: 431-436.
12. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005; 15: 4050-4053.
13. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005; 129: 776-783.
14. Facon T, Mary J, Hulin C, et. al. Major superiority of melphalan-prednisone (MP)+ thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood. 2006; 106: 230a.
15. Harousseau J, Marit G, Caillot D, et al. VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenterphase II trial. Blood. 2006; 108: 56a.
16. Dimopoulos MA, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Eng J Med. 2007: 357: 2123-2133.
17. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethason for relapsed or refractory multiple myeloma in North America. N Eng J Med. 2007; 357: 2133-2142.
18. San Miguel I, Schlag R, Khuageva NK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Eng J Med. 2008; 359: 906-917.
19. Attal M, Harousseau JL, Leyvraz S, et. al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108: 3289-3294.